C14orf166B Inhibitors
C14orf166B inhibitors encompass a range of compounds that alter various intracellular signaling pathways, ultimately leading to the diminution of C14orf166B activity. For instance, some of these inhibitors target key kinases, impeding phosphorylation events crucial for the proper functioning of C14orf166B. By inhibiting kinase activities, these compounds effectively reduce the phosphorylation-dependent activation of C14orf166B, ensuring a decrease in its overall activity within the cell. Moreover, certain inhibitors act on pathways upstream of C14orf166B, such as the PI3K/AKT/mTOR and MAPK/ERK pathways. These pathways are integral to the regulation of C14orf166B, and their obstruction leads to a cascade of effects that culminate in the suppression of C14orf166B's activity.
Additionally, other inhibitors interfere with the stability and expression levels of proteins that regulate C14orf166B's functional state. Histone deacetylase inhibitors, for instance, can alter gene expression patterns, which may include genes coding for proteins that modulate C14orf166B activity. Proteasome inhibitors contribute to the inhibition of C14orf166B by preventing the degradation of its regulatory proteins, thus impeding the protein's ability to carry out its functions. Furthermore, specific inhibitors target enzymes like JNK and p38 MAPK, which are pivotal in signaling pathways that indirectly govern the activity of C14orf166B.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can inhibit multiple kinases that phosphorylate C14orf166B, leading to its decreased activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, a kinase involved in C14orf166B regulation, thereby reducing C14orf166B's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, impeding the PI3K/AKT/mTOR pathway which is known to regulate C14orf166B activity, resulting in its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, which by blocking the PI3K/AKT pathway, reduces the phosphorylation and subsequent activity of C14orf166B. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can change the chromatin structure and modulate gene expression, thereby inhibiting the activity of regulatory proteins such as C14orf166B. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream in the MAPK/ERK pathway, leading to reduced activation of downstream proteins including C14orf166B. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor, which by inhibiting JNK can decrease the phosphorylation of proteins that interact with C14orf166B, indirectly inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can inhibit the phosphorylation of substrates involved in the regulation of C14orf166B's activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of regulatory proteins that control C14orf166B's activity, leading to its functional inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which can modulate the actin cytoskeleton and related signaling, thus indirectly affecting the function of C14orf166B. | ||||||